Figure 3. Results from a retrospective analysis of a nationwide cohort of Korean AMI patients. During a 1-year follow-up period after index PCI, ischemic outcomes and bleeding outcomes were analyzed. Compared with clopidogrel (AC), new generation P2Y12 receptor inhibitors prasugrel (AP) and ticagrelor (AT) could not decrease ischemic outcomes, while significantly increased bleeding outcomes. Consistent results were shown in multivariate cox regression analysis, propensity score matching analysis, inverse probability weighted regression analysis, and pooled analysis after multiple imputation. This figure was modified from the original version.³²⁾.

AMI = acute myocardial infarction; CI = confidence interval; DAPT = dual antiplatelet therapy; HR = hazard ratio; MACCE = major adverse cardiac and cerebral events; PCI = percutaneous coronary intervention.